Eric M. Toloza

Eric M. Toloza

Auto-generated profile, based on publicly available information

Eric M. Toloza

Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in The Cancer Journal
Verified
Journal Article
Open access
JMJohn E. Mullinax
John E. Mullinax
MEMichael Egger
Michael Egger
MMMartin McCarter
Martin McCarter
BMBradley J. Monk
Bradley J. Monk
ETEric M. Toloza
Eric M. Toloza
ASAmod Sarnaik
Amod Sarnaik
Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs), an investigational cellular therapy, has demonstrated antitumor efficacy in patients with advanced solid tumors, including melanoma. Tumor-infiltrating lymphocyte cell therapy involves surgical resection of a patient's tumor, ex vivo TIL expansion under conditions that overcome immunosuppressive responses elicited by the tumor and the tumor microenvironment, administration of a lymphodepleting regimen, and infusion of the final TIL cell therapy product back into the patient followed by interleukin 2 administration to support T-cell activity. The surgeon plays a central role in patient identification and tumor selection—steps that are critical for successful outcomes of TIL cell therapy. Commercialization of TIL cell therapy and its broader access to patients will require education and collaboration among surgeons, oncologists, and cellular therapists. This review highlights the unique role that surgeons will play in the implementation of TIL cell therapy and serves as a contemporary report of best practices for patient selection and tumor resection methods.

1 November 2016 in Surgery
Verified
Journal Article
Closed access
KTKavian Toosi
Kavian Toosi
FVFrank O. Velez-Cubian
Frank O. Velez-Cubian
JGJessica Glover
Jessica Glover
ENEmily P. Ng
Emily P. Ng
CMCarla C. Moodie
Carla C. Moodie
ETEric M. Toloza
Eric M. Toloza

1 December 2016 in The American Journal of Surgery
Verified
Journal Article
Closed access
MEMaria F. Echavarria
Maria F. Echavarria
ACAnna M. Cheng
Anna M. Cheng
FVFrank O. Velez-Cubian
Frank O. Velez-Cubian
ENEmily P. Ng
Emily P. Ng
CMCarla C. Moodie
Carla C. Moodie
ETEric M. Toloza
Eric M. Toloza

1 July 2015 in Cancer Control
Verified
Journal Article
Open access
PDF file
FVFrank O. Velez-Cubian
Frank O. Velez-Cubian
ENEmily P. Ng
Emily P. Ng
JFJacques P. Fontaine
Jacques P. Fontaine
ETEric M. Toloza
Eric M. Toloza
Despite initial concerns about the general safety of videothoracoscopic surgery, minimally invasive videothoracoscopic surgical procedures have advantages over traditional open thoracic surgery via thoracotomy. Robotic-assisted minimally invasive surgery has expanded to almost every surgical specialty, including thoracic surgery. Adding a robotic-assisted surgical system to a videothoracoscopic surgical procedure corrects several shortcomings of videothoracoscopic surgical cameras and instruments. We performed a literature search on robotic-assisted pulmonary resections and compared the published robotic series data with our experience at the H. Lee Moffitt Cancer Center & Research Institute. All perioperative outcomes, such as intraoperative data, postoperative complications, chest tube duration, hospital length of stay (LOS), and in-hospital mortality rates were noted. Our literature search found 23 series from multiple surgical centers. We divided the literature into 2 groups based on the year published (2005–2010 and 2011–2014). Operative times from earlier studies ranged from 150 to 240 minutes compared with 90 to 242 minutes for later studies. Conversion rates (to open lung resection) from the earlier studies ranged from 0% to 19% compared with 0% to 11% in the later studies. Mortality rates for the earlier studies ranged from 0% to 5% compared with 0% to 2% for the later studies. Since 2010, our group has performed more than 600 robotic-assisted thoracic surgical procedures, including more than 200 robotic-assisted pulmonary lobectomies, which we also divided into 2 groups. Our median skin-to-skin operative time improved from 179 minutes for our early group (n = 104) to 172 minutes for our later group (n = 104). The overall conversion rate was 9.6% and the emergent conversion rate (for bleeding) was 5% for our robotic-assisted lobectomies. The most common postoperative complications in our cohort were prolonged air leak (>7 days; 16.8%) and atrial fibrillation (12%). Hospital LOS for the early series ranged from 3 to 11 days compared with 2 to 6 days for the later series. Median hospital LOS decreased from 6 to 4 days. Our mortality rate was 1.4%; 3 in-hospital deaths occurred in the early 40 cases. Mediastinal lymph node (LN) dissection and detection of occult mediastinal LN metastases were improved during robotic-assisted lobectomy for non–small-cell lung cancer, as demonstrated by an overall 30% upstaging rate, including a 19% nodal upstaging rate, in our cohort. Robotic-assisted videothoracoscopic pulmonary lobectomy appears to be as safe as conventional videothoracoscopic surgical lobectomy, which has decreased perioperative complications and a shorter hospital LOS than open lobectomy. Both mediastinal LN dissection and the early detection of occult mediastinal LN metastatic disease were improved by robotic-assisted videothoracoscopic surgical compared with conventional videothoracoscopic surgical or open thoracotomy.

1 September 2016 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
FVFrank O. Velez-Cubian
Frank O. Velez-Cubian
KRKathryn L. Rodriguez
Kathryn L. Rodriguez
MTMatthew R. Thau
Matthew R. Thau
CMCarla C. Moodie
Carla C. Moodie
JGJoseph R. Garrett
Joseph R. Garrett
ETEric M. Toloza
Eric M. Toloza
Background: We investigated whether robotic-assisted surgery improves mediastinal lymph node dissection (MLND). Methods: We analyzed patients (pts) who underwent robotic-assisted video-assisted thoracoscopic surgery (R-VATS) lobectomy for non-small cell lung cancer (NSCLC) over 36 months. Perioperative outcomes, tumor histology, numbers, locations, and status of all lymph nodes (LNs), and TNM (tumor, nodal, and metastasis) stage changes were analyzed. Results: One hundred fifty-nine pts had mean tumor size 3.3±0.2 cm, most commonly being adenocarcinoma. Assessment of ≥3 N2 stations occurred in 156 (98.1%) pts, with 141 (88.7%) pts having >3 N2 stations reported. Mean total N1 + N2 stations assessed was 5.6±0.1 stations, including mean 4.1±0.1 N2 stations assessed. Mean N2 LNs reported was 7.2±0.3 LNs, and mean total N1 + N2 LNs reported was 13.4±0.4 LNs. There were 118 (74.2%) clinical stage-I pts versus 96 (60.4%) pathologic stage-I pts. Overall, 48 (30.2%) pts were upstaged, including 13 pts with cN0–pN1, 13 pts with cN0–pN2, 4 pts with cN1–pN2, and 18 pts with changes in T. Conclusions: R-VATS lobectomy is safe and results in perioperative outcomes comparable to those reported for conventional VATS. R-VATS MLND is effective at detecting occult metastatic disease during lobectomy for NSCLC.

27 January 2017 in Surgical Innovation
Verified
Journal Article
Closed access
BMBryce Montané
Bryce Montané
KTKavian Toosi
Kavian Toosi
FVFrank O. Velez-Cubian
Frank O. Velez-Cubian
MEMaria F. Echavarria
Maria F. Echavarria
MTMatthew R. Thau
Matthew R. Thau
ETEric M. Toloza
Eric M. Toloza
Objective. We investigated whether higher body mass index (BMI) affects perioperative and postoperative outcomes after robotic-assisted video-thoracoscopic pulmonary lobectomy. Methods. We retrospectively studied all patients who underwent robotic-assisted pulmonary lobectomy by one surgeon between September 2010 and January 2015. Patients were grouped according to the World Health Organization’s definition of obesity, with “obese” being defined as BMI >30.0 kg/m2. Perioperative outcomes, including intraoperative estimated blood loss (EBL) and postoperative complication rates, were compared. Results. Over 53 months, 287 patients underwent robotic-assisted pulmonary lobectomy, with 7 patients categorized as “underweight,” 94 patients categorized as “normal weight,” 106 patients categorized as “overweight,” and 80 patients categorized as “obese.” Because of the relatively low sample size, “underweight” patients were excluded from this study, leaving a total cohort of 280 patients. There was no significant difference in intraoperative complication rates, conversion rates, perioperative outcomes, or postoperative complication rates among the 3 groups, except for lower risk of prolonged air leaks ≥7 days and higher risk of pneumonia in patients with obesity. Conclusions. Patients with obesity do not have increased risk of intraoperative or postoperative complications, except for pneumonia, compared with “normal weight” and “overweight” patients. Robotic-assisted pulmonary lobectomy is safe and effective for patients with high BMI.